Medical Hypotheses
Volume 57, Issue 1 , Pages 46-50 , July 2001

Sickle cell disease: a chronic inflammatory condition

Received 10 October 2000 ,Accepted 10 October 2000.

References 

    REFERENCES
  1. Buchanan GR, Glader BE. Leukocyte counts in children with sickle cell disease. Comparative values in the steady state, vasoocclusive crisis, and bacterial infection. Am J Dis Child. 1978;132:396–398
  2. De Ceulaer K, Pagliuca A, Forbes M, Maude GH, Serjeant BE. Recurrent infections in sickle cell disease: haematological and immune studies. Clin Chim Acta. 1985;148:161–165
  3. Mendoza E, Gutgsell N, Temple JD, Issitt P. Monocyte phagocytic activity in sickle cell disease. Acta Haematol. 1991;85:199–201
  4. Gorham JD, Güler ML, Steen RG, Mackey AJ, Daly MJ, Frederick K, et al. Genetic mapping of a murine locus controlling development of T helper 1/T helper 2 type responses. Proc Natl Acad Sci USA. 1996;93:12467–12472
  5. Taylor SC, Shacks SJ, Qu Z. In vivo production of type 1 cytokines in healthy sickle cell disease patients. J Natl Med Assoc. 1999;91:619–624
  6. Taylor SC, Shacks SJ, Qu Z, Wiley P. Type 2 cytokine serum levels in healthy sickle cell disease patients. 1997; p. 753–757
  7. Lachant NA, Oseas RS. Vasoocclusive crisis-associated neutrophil dysfunction in patients with sickle-cell disease. Am J Med Sci. 1987;294:253–257
  8. Raport CJ, Gosling J, Schweickart VL, Gray PW, Charo IF. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta and MIP-1alpha. J Biol Chem. 1996;271:17161–17166
  9. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381:667–673
  10. Chies JAB, Hutz M. Alta frequência do alelo CCR5Δ32 em indivı́duos com anemia falciforme. Genet Mol Biol. 1999;22:738
  11. Meyer L, Magierowska M, Hubert JB, Mayaux MJ, Misrahi M, LeChenadec J, et al. CCR5 delta32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1. The SEROCO-HEMOCO-SEROGEST Study Groups. J Infect Dis. 1999;180:920–924
  12. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol. 1999;163:6236–6243
  13. Nguyen GT, Carrington M, Beeler JA, Dean M, Aledort LM, Blatt PM, et al. Ohenotypic expressions of CCR-5 delta32/delta32 homozygosity. J Acquir Immune Defic Syndr. 1999;22:75–82
  14. Loetscher P, Bordoli L, Baggiolini M, Moser B, Chizzolini C, Dayer JM. CCR5 is characteristic of Th1 lymphocytes. Nature. 1998;6665:344–345
  15. Croizat H. and Nagel R.>L. Circulating cytokines response and the level of erythropoiesis in sickle cell anemia. Am J Hematol. 1999;60:105–115
  16. Neonato MG, Lu CY, Guillooud-Bataille M, Lapoumeroulie C, Nabeel-Jassim H, Dabit D, et al. Besmond C. Elion J. Genetic polymorphism of the mannose-binding protein gene in children with sickle cell disease: identification of three new variant alleles and relationship to infections. Eur J Hum Genet. 1999;7:679–686
  17. Kaul DK. and Hebbel R. P. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106:411–420
  18. Saleh AW, Duits AJ, Gerbes A, De Vries C, Hillen HF. Cytokines and soluble adhesion molecules in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol. 1998;100:26–31
  19. Satoh Y, Powers C, Toledo LM, Kowalski TJ, Peters PA, Kimble EF. Derivatives of 2-[[N-Aminocarbonyl)]-N-hydroxyamino]methyl]-1,4-benzodiaxan as orally active 5-lipoxygenase inhibtors. J Med Chem. 1995;38:68–75
  20. Cai X, Scannell RT, Yaeger D, Hussoin MS, Killian DB, Qian C, et al. (+/–)-trans-2-[3-methoxy-4-(4 chlorophenylthioethoxy)-5-(N-methyl-N-hydroxyureidyl) methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibtor and platelet-activating factor receptor antagonist. J Med Chem. 1998;41:1970–1979
  21. Malamas MS, Carlson RP, Grimes D, Howell R, Glaser K, Gunawan I, et al. Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase. J Med Chem. 1996;39:237–245
  22. Connolly PJ, Wetter SK, Beers KN, Hamel SC, Chen RH, Wachter MP, et al. N-hydroxyurea and hydroxamic acid inhibtors of cyclooxygenase and 5-lipoxygenase. Bioorg Med Chem Lett. 1999;9:979–984
  23. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exerceise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med. 1996;153:931–935
  24. Hasday JD, Meltzer SS, Moore WC, Wisniewski P, Hebel JR, Lanni C, et al. Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. Am J Respir Crit Care Med. 2000;161:1229–1236
  25. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106:337–338

PII: S0306-9877(00)91310-0

doi: 10.1054/mehy.2000.1310

Medical Hypotheses
Volume 57, Issue 1 , Pages 46-50 , July 2001

Article Tools